Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Modzatinib · ATI-2138

Small molecule · developed by Aclaris Therapeutics

Phase 2 Most advanced trial
ACRS Developer
2 Registered trials

What is Modzatinib?

Modzatinib (ATI-2138) is a drug studied in lichen planus and atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ATI-2138
Drug type
Small molecule
Therapy area
Dermatology, Immunology
Developer
Aclaris Therapeutics, Inc. (ACRS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
JKD3CP7SWF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07935590 Phase 2 Lichen Planus Not yet recruiting ACRS
NCT06585202 Phase 2 Atopic Dermatitis Completed ACRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lichen PlanusAtopic Dermatitis

More from Aclaris Therapeutics

Follow ACRS, the company behind Modzatinib

See ACRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACRS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.